Latest studies
- Completed
European Carotid Surgery Trial 2
This study looks at whether people with narrowed neck arteries and a low-to-medium risk of stroke need an operation or stent, or if modern medications alone are just as safe. It compares optimal tablets and lifestyle advice against having a procedure alongside modern medical treatment.
StrokeSwitzerland - CompletedNot Applicable
An international multicentre study of tamoxifen versus placebo in women at increased risk of breast cancer
This study looks at whether a daily medicine called tamoxifen can lower the risk of breast cancer in women who have a higher chance of developing it. Researchers compare tamoxifen with a dummy pill (placebo) to find out how safe and effective it is at preventing the disease.
Breast cancer chemopreventionSwitzerland - CompletedPhase II
A trial of BEvACizumab added to temozolomide +/- irinOtecan for children with refractory/relapsed Neuroblastoma
This study looks at new treatment combinations for children and young people with neuroblastoma that has returned or stopped responding to standard therapy. Researchers want to see if adding an antibody drug called bevacizumab to chemotherapy can help control the cancer and improve treatment options.
Neuroblastoma in children aged ≥1 to ≤21 yearsSwitzerland - Completed
A study to evaluate diagnostic tests used at the point of care for improving antibiotic prescribing for patients with respiratory tract infections in primary care in Europe
Antibiotics treat bacterial infections, but taking them when not needed makes them less effective over time. This European study checks whether rapid clinic tests can help GPs decide if patients with coughs or sore throats truly need antibiotics, safely cutting down unnecessary prescriptions without harming patient recovery.
Community-acquired acute respiratory tract infectionSwitzerland - Completed
No routine measurement of gastric residual volume in paediatric critical care
Children in intensive care need good nutrition through a feeding tube to help them heal. Doctors usually use a syringe to check fluid in the stomach every six hours, which can pause feeding. This study looks at whether stopping these routine checks safely allows children to get more of their required food.
Oral and GastrointestinalSwitzerland - RecruitingPhase II
A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
This study is testing a new capsule called ZED1227 for adults with coeliac disease. Researchers want to see if this medicine can protect the gut and ease lingering tummy symptoms caused by accidental gluten exposure, even in people who already follow a strict gluten-free diet.
Coeliac diseaseSwitzerland - RecruitingPhase I/II
A trial looking at different treatments for neuroblastoma which has come back after initial therapy
The BEACON2 trial is testing new combinations of cancer medicines for children and young people whose neuroblastoma has returned or worsened after initial treatment. The goal is to find out which drug combinations are safest and work best to control the disease and improve future care.
Relapsed NeuroblastomaSwitzerland - RecruitingPhase III
A study of the anti-inflammatory medication colchicine for people with blocked arteries of the legs
Peripheral arterial disease (PAD) causes narrowed blood vessels in the legs. This clinical trial is testing whether an anti-inflammatory tablet called colchicine can help protect arteries and reduce the risk of serious complications, such as heart attacks, strokes, and leg amputations, in people living with PAD.
Peripheral artery diseaseSwitzerland - CompletedNot Applicable
Evaluating the use of a lower blood pressure target to guide drug treatment in critically ill children with low blood pressure
This UK study looks at critically ill children in intensive care who have low blood pressure. Doctors want to see if aiming for a slightly lower, safe blood pressure target reduces the amount of strong medicine needed. This could help children recover better and avoid unwanted side effects from intensive treatments.
Critically ill children with hypotensionSwitzerland - RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
Ovarian Cancer RecurrentSwitzerland - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)Switzerland - RecruitingPhase III
Tranexamic acid (and Desmopressin) for very early bleeds in the brain
This clinical trial tests whether an affordable medicine called tranexamic acid can stop bleeding in the brain after a stroke. Doctors want to see if giving this injection quickly in the emergency room helps people survive with less long-term disability, improving recovery and everyday life six months later.
Hyperacute primary intracerebral haemorrhage (stroke)Switzerland - Completed
Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with mild, moderate or severe skin conditions
Acne is a common skin condition that affects confidence and well-being. This study tests whether a daily skincare routine using Eucerin products helps clear mild to severe spots. Researchers want to see how well these creams work over a year in people aged 12 to 50 across the UK and worldwide.
Subjects with acne-prone skin aged 12-50 years with Investigator's Global Assessment (IGA) grades 2-4, evaluating treatment of mild to severe acne vulgaris.Switzerland - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseSwitzerland - CompletedPhase III
MyeChild 01: Treating children with acute myeloid leukaemia
MyeChild 01 is a clinical trial for children and young people with acute myeloid leukaemia (AML). It tests whether adding a targeted drug called gemtuzumab ozogamicin to standard chemotherapy helps clear leukaemia cells more effectively and safely. It also looks at the best chemotherapy combinations before a stem cell transplant.
Acute myeloid leukaemiaSwitzerland - Completed
A multi-site observational study looking at the risk factors associated with tooth sensitivity, receding gums and tooth wear
This study looks into why adults develop sensitive teeth, receding gums, and worn tooth enamel. Researchers are studying how diet, brushing, and lifestyle affect oral health across Europe. Taking part is simple: it involves completing a short lifestyle survey and having a gentle mouth check-up during a single dental appointment.
Dentine hypersensitivity Tooth wear Recession Clinical loss of attachment Oral hygiene habits Dietary habitsSwitzerland - Recruiting
Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation
This study looks back at information from hospitals to understand serious problems that can happen during or soon after a heart procedure called ablation for fast or extra heartbeats (VT/PVC). Researchers want to find out why these problems occur and how they were managed.
Ventricular Tachycardia (VT)Premature Ventricular ComplexesSwitzerland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study is testing a new drug (INCA33890) alongside standard chemotherapy and another medicine (bevacizumab) for advanced bowel cancer that has spread. It aims to see if adding INCA33890 is safe and helps people live longer and feel better.
CRC (Colorectal Cancer)Switzerland - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseSwitzerland - Active not recruitingPHASE3
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
This study compares two treatments, ripretinib and sunitinib, for advanced GIST (a type of cancer) in patients who have already been treated with imatinib. It aims to see which treatment works best.
Gastrointestinal Stromal TumorsSwitzerland - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerSwitzerland - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
High-Risk NeuroblastomaPatient With Insufficient Response ChemoimmunotherapySwitzerland - Active not recruitingPHASE3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
This study is for people in the UK with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has returned or not responded to previous treatments. It aims to see if adding an experimental drug, brentuximab vedotin, to two existing treatments (rituximab and lenalidomide) works better than the two existing treatments alone.
Diffuse Large B-cell LymphomaSwitzerland - Enrolling by invitationPHASE3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study looks at a new treatment called Selatogrel for people who have recently had a heart attack and are at risk of another. It checks if taking Selatogrel when symptoms start can help prevent a second heart attack.
Acute Myocardial InfarctionSwitzerland - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaSwitzerland - RecruitingPHASE1, PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
This study looks at a new drug, sacituzumab tirumotecan, alone or with other common treatments for advanced bowel, pancreatic, and bile duct cancers. Researchers want to see if it's safe, tolerable, and can shrink these cancers.
Colorectal CancerPancreatic Ductal AdenocarcinomaBiliary Tract CancerSwitzerland - Available
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
This program offers people with advanced ALK-positive lung cancer or other ALK-positive tumours an opportunity to receive an investigational medicine called neladalkib (NVL-655). It is for those who can't join a regular trial and have run out of other good treatment options.
Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)Switzerland - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
This study compares a new combination medicine, BMS-986489 (BMS-986012 and Nivolumab), with a standard treatment (Atezolizumab), both given with chemotherapy. It's for people with a type of lung cancer called extensive-stage small cell lung cancer who are starting their first treatment.
Extensive-Stage Small Cell Lung CancerSwitzerland - Active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
Multiple MyelomaSwitzerland - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
Non-Small Cell Lung CancerSwitzerland - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
Large B-Cell LymphomaSwitzerland - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Switzerland - Active not recruitingPHASE3
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
This study compares two drug combinations – camizestrant with palbociclib, and anastrozole with palbociclib – for advanced breast cancer. It's for patients whose cancer has specific hormone features and hasn't yet been treated for its advanced stage. The goal is to find a better first treatment.
ER-Positive HER2-Negative Breast CancerSwitzerland - RecruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
Breast NeoplasmsSwitzerland - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaSwitzerland - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesSwitzerland - RecruitingPHASE3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is testing a new drug, odronextamab, for adults with follicular lymphoma that hasn't been treated before. It aims to find out if the drug is safe and how well it works compared to current standard treatments.
Follicular Lymphoma (FL)Switzerland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseSwitzerland - Active not recruitingPHASE3
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
This study looks at a new medicine called remibrutinib for chronic spontaneous urticaria (CSU), comparing it to a dummy treatment (placebo) and another existing medicine, omalizumab. It aims to see if remibrutinib is safe and helps reduce hives and itching in adults whose CSU isn't well controlled by usual allergy medicines.
Chronic Spontaneous UrticariaSwitzerland - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study is looking at a new combination of medicines for a certain type of advanced breast cancer. It compares a new drug, inavolisib, with existing treatments to see if it's more effective and safe for people whose cancer has a specific genetic change (PIK3CA mutation).
Breast CancerSwitzerland - RecruitingPHASE3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
This study is looking into a new medicine called Seladelpar for people with a liver condition called Primary Biliary Cholangitis (PBC) and mild liver scarring (cirrhosis). It aims to see how well Seladelpar works compared to a dummy pill to improve health outcomes.
Primary Biliary CholangitisSwitzerland - Enrolling by invitationPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
This study is for cancer patients who have already been in another durvalumab drug trial and are still benefiting from the treatment. It lets them continue receiving the drug to see if it keeps helping them.
CancerSwitzerland - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaSwitzerland - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerSwitzerland - RecruitingNA
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
This study compares two common medical devices, the Medtronic Endurant and Gore Excluder, used to treat a condition called Abdominal Aortic Aneurysm (AAA). It aims to see how well they shrink the aneurysm over time.
Abdominal Aortic AneurysmAbdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder)Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)Switzerland - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
Gastric CancerGastroesophageal Junction CancerSwitzerland - Active not recruitingPHASE3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
This study looks at the long-term safety and effectiveness of a medicine called ofatumumab for people with relapsing MS. It also checks how well vaccines work in people taking this medicine, including those for flu, pneumonia, tetanus, and COVID-19.
Relapsing Multiple SclerosisSwitzerland - Active not recruitingPHASE3
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
This study is looking at a new way to treat advanced head and neck cancer. It combines a drug called pembrolizumab with surgery and radiotherapy, aiming to improve how long people live without the cancer returning compared to standard treatment.
Head and Neck NeoplasmsSwitzerland - RecruitingPHASE3
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
This study is testing a new medicine, Ris-Rez, for advanced small cell lung cancer that has come back. It aims to see if Ris-Rez works better than standard treatment (topotecan) to shrink tumours and help people live longer, while also checking its safety.
Neoplasms, LungSwitzerland - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)Switzerland